menu
    • menu
    [{"orgOrder":0,"company":"Leal Therapeutics","sponsor":"Chugai Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"LTX-002","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Leal Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Leal Therapeutics \/ Chugai Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Leal Therapeutics \/ Chugai Venture Fund"},{"orgOrder":0,"company":"Leal Therapeutics","sponsor":"SV Health Investors'DDF","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"LTX-001","moa":"GLS1","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Leal Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Leal Therapeutics \/ SV Health Investors'DDF","highestDevelopmentStatusID":"5","companyTruncated":"Leal Therapeutics \/ SV Health Investors'DDF"}]

    Find Clinical Drug Pipeline Developments & Deals by Leal Therapeutics

    Menu

    Leal Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Leal Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Leal Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTX-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : SV Health Investors'DDF

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Leal Therapeutics Announces Series A to Progress First-In-Class Neuro-Metabolic Therapies

                            Details : The proceeds from the Series A financing will be used to advance LTX-001 through a clinical trial in schizophrenia patients.

                            Product Name : LTX-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 27, 2025

                            Lead Product(s) : LTX-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : SV Health Investors'DDF

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Leal Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Leal Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTX-002

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Chugai Venture Fund

                            Deal Size : $45.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Leal Secures $45M to Advance Neurodegenerative And Psychiatric Therapies

                            Details : The proceeds will be used to advance Leal's pipeline of ASO lead programs, which includes LTX-002 for the treatment of patients with genetic or sporadic amyotrophic lateral sclerosis.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            October 30, 2024

                            Lead Product(s) : LTX-002

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Chugai Venture Fund

                            Deal Size : $45.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth